Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P08514
UPID:
ITA2B_HUMAN
Alternative names:
GPalpha IIb; Platelet membrane glycoprotein IIb
Alternative UPACC:
P08514; B2RCY8; O95366; Q14443; Q17R67
Background:
Integrin alpha-IIb, also known as GPalpha IIb and Platelet membrane glycoprotein IIb, plays a pivotal role in hemostasis by mediating platelet aggregation. This protein acts as a receptor for various ligands including fibronectin, fibrinogen, and vitronectin, recognizing specific sequences that facilitate platelet interactions and clot formation.
Therapeutic significance:
Mutations in Integrin alpha-IIb are linked to Glanzmann thrombasthenia 1, characterized by impaired platelet aggregation, and to a form of congenital macrothrombocytopenia, affecting platelet production. Targeting the pathways involving Integrin alpha-IIb offers promising avenues for treating these platelet disorders.